Register Login

FibroGen Inc (FGEN)

(75% Positive) FIBROGEN, INC. (FGEN) Announces Enrollment Update for currently Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 7, 2026, 9:17 p.m.

    📋 FIBROGEN, INC. (FGEN) - Clinical Trial Update

    Filing Date: 2026-01-07

    Accepted: 2026-01-07 16:15:12

    Event Type: Clinical Trial Update

    Event Details:

    FibroGen Inc (FGEN) Announces Clinical Trial Update FibroGen Inc (FGEN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: currently
    • Clinical Stage: Phase 2
    • Collaboration: Company
      • Targeting PET Imaging Agent) •Topline results from the investigator-sponsored Phase 1b/2 study, conducted by UCSF, of FG-3246
      • targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180
      • Targeting ADC) and FG-3180

    🔬 Clinical Development Pipeline (FIBROGEN, INC.):

    Product Type Development Stage Therapeutic Area Source
    FG-3246 DRUG Phase PHASE2 Metastatic Castration-Resistant Prostate Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: FibroGen Inc
    • CIK: 0000921299
    • Ticker Symbol: FGEN
    • Period End Date: 2026-01-07
    • Document Type: 8-K

Search

News categories